High level of multidrug resistance mutations in HIV type 1 pol gene and resistance-associated mutations to enfuvirtide (T-20) among antiretroviral- experienced patients from central Brazil

AIDS Research and Human Retroviruses

Volumn 25, Issue 10, 2009, Pages 943-950

  Cardoso, Ludimila Paula Vaz ^a   De Araújo Stefani, Mariane Martins ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; GLYCOPROTEIN GP 41; NEVIRAPINE; NEVIRAPINE PLUS ZIDOVUDINE; RNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; RNA SEQUENCE; SCHOOL CHILD; VERTICAL TRANSMISSION; VIRAL GENETICS; VIRUS GENE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BRAZIL; CHILD; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 70449467630     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0060     Document Type: Article

References (34)

1. Petrella M, Brenner B, Loemba H, and Wainberg MA: HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries. Drug Resist Update 2001;4:339-346.
2. Lalezari JP, Henry K, O'HearnM, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
3. Xu L, Hue S, Taylor S, et al.: Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral naïve and experienced patients. AIDS 2002;16:1684-1686.
4. Brindeiro RM, Diaz RS, Sabino EC, et al.: Brazilian Network for HIVDrug Resistance Surveillance (HIV-BResNet):Asurvey of chronically infected individuals. AIDS 2003;17:1063-1069.
5. Briacute;gido LF, Franco HM, Custodio RM, et al.: Molecular characteristics of HIV type 1 circulating in São Paulo, Brazil. AIDS Res Hum Retroviruses 2005;21:673-682.
6. Sa-Filho DJ, Sanabani S, Diaz RS, et al.: Analysis of full-length human immunodeficiency virus type 1 genome reveals a variable spectrum of subtypes B and F recombinants in São Paulo, Brazil. AIDS Res Hum Retroviruses 2005;21:145-151.
7. Sa-Filho DJ, Sucupira MC, Caseiro MM, Sabino EC, Diaz RS, and Janini LM: Identification of two HIV type 1 circulating recombinant forms in Brazil. AIDS Res Hum Retroviruses 2006;22:1-13.
8. Guimarã es ML, Eyer-Silva WA, Couto-Fernandez JC, and Morgado MG: Identification of two new CRF-BF in Rio de Janeiro State, Brazil. AIDS 2008;22:433-438.
9. Pereira GA, Stefani MM, Martelli CM, et al.: Human immunodeficiency virus type 1 and hepatitis C virus coinfection and viral subtypes at an HIV testing center in Brazil. J Med Virol 2006;78:719-723.
10. Cavalcanti AM, Lacerda HR, Brito AM, Pereira S, Medeiros D, and Oliveira S: Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil. Mem Inst Oswaldo Cruz 2007;102:785-792.
11. Medeiros MS, Arruda EAG, Guerrant RL, et al.: Genotype testing and antiretroviral resistance profiles from HIV-1 patients experiencing therapeutic failure in Northeast Brazil. Braz J Infect Dis 2007;11:390-394.
12. Stefani MM, Pereira GA, Lins JA, et al.: Molecular screening shows extensive HIV-1 genetic diversity in central west Brazil. J Clin Virol 2007;39:205-209.
13. Véras NMC, Véras VS, Ramalho E, et al.: HIV type 1 genetic variability in Central Brazil. AIDS Res Hum Retroviruses 2007;23:1481-1489.
14. Lehvaslaiho H, Hide W, and Oliveira T: South African National Bioinformatics Institute, University of Western Cape, South Africa. http:==www.sanbi.ac.za. Accessed January, 2009.
15. Hall TA: BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95=98=MT. Nucleic Acids Symp Ser 1999;41:95-98.
16. Los Alamos HIV database: http:==ww.hiv.lanl.gov. Accessed February, 2009.
17. Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-3800.
18. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG: The CLUSTAL-X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
19. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16:111-120.
20. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.
21. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, and Novak NG: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
22. Stanford HIV Resistance Database: Antiretroviral drug summaries: Enfuvirtide (ENF, Fuzion). http:==hivdb.stanford.edu. Accessed February, 2009.
23. Los Alamos HIV Drug Resistance Database: http:==resdb.lanl.gov=Resist-DB. Accessed February, 2009.
24. Eshleman SH, Hudelson SE, Bruce R, et al.: Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains. AIDS Res Hum Retroviruses 2007;23:1593-1598.
25. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
26. Sucupira MC, Souza IE, Costa LJ, Scheinberg MA, and Diaz RS: Antiretroviral treatment failure and HIV-1 genotypic resistance in Sao Paulo, Brazil. Antiviral Ther 2001;6:263-264.
27. Brito AM, 2, Castilho EA, and Szwarcwald CL: Regional patterns of the temporal evolution of the AIDS epidemic in Brazil following the introduction of antiretroviral therapy. BJID 2005;9:9-19.
28. Moore JP and Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003;100:10598-10602.
29. Robertson D: US FDA approves new class of HIV therapeutics. Nat Biotechnol 2003;21:470-471.
30. Poveda E, Rodés B, Labernardière JL, et al.: Evolution of genotypic and phenotypic resistance to enfuvirtide in HIVinfected patients experiencing prolonged virologic failure. J Med Virol 2004;74:21-28.
31. Si-Mohamed A, Piketty C, Tisserand P, et al.: Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2007;44:1-5.
32. Oliveira ACA, Martins AN, Pires AFNPC, et al.: Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C and F isolates from Brazilian patients failing HAART. AIDS Res Hum Retroviruses 2009;25:193-198.
33. Stefani MM, Pereira GA, Martelli CM, Shindo N, and Galvao-Castro B: Evidence of HIV-1 genetic diversity among pregnant women with AIDS or infected with HIV-1 in Central Brazil. J Acquir Immune Defic Syndr 2000;2:205-207.
34. Pereira GA, Stefani MM, Araú jo-Filho JA, Souza LC, Stefani GP, and Martelli CM: Human immunodeficiency virus type 1 (HIV-1) and Mycobacterium leprae co-infection: HIV-1 subtypes and clinical, immunologic, and histopathologic profiles in a Brazilian cohort. Am J Trop Med Hyg 2004;71: 679-684.